- Seborrhoeic dermatitis is a common, long-term inflammatory rash of the scalp, face, eyebrows, ears and skin folds. A 2025 review by Piacentini and colleagues says Malassezia yeast is "not the direct cause" of it, and that immune over-reaction and barrier change are central (Piacentini et al. 2025).
- The largest systematic review, a Cochrane review of 51 trials with 9,052 people, found 2% ketoconazole cleared fewer patients' rashes than placebo (failure risk ratio 0.69, 95% CI 0.59 to 0.81). Ketoconazole was similar to topical steroids for clearing the rash, with fewer side effects (Okokon et al., Cochrane 2015).
- Zinc pyrithione shampoo helped too, but in the one head-to-head trial cited in the literature it did slightly worse than ketoconazole: 67% vs 73% dandruff improvement at week 4 (Tynes et al. 2024, summarising Pierard-Franchimont 2002). The zinc pyrithione efficacy studies we could find were reported by its maker, Procter & Gamble.
- In babies, cradle cap is usually harmless and often settles on its own. The Cochrane review of infantile seborrhoeic dermatitis found six trials with 310 children, all of very low certainty, and no trials of the mineral oils, salicylic acid or antifungals that clinicians use (Victoire et al., Cochrane 2019).
- Topical steroids clear flares fast, but facial use carries a risk of skin thinning, dilated blood vessels and worsening rosacea. New Zealand's medicines regulator advises facial use for no more than two weeks (Medsafe 2005).
- Money trail: Ketoconazole was developed by Janssen, part of Johnson & Johnson, and the European rights were sold to the German generics firm Stada in 2018, and the announcement put the brand's 2017 EMEA sales at about EUR 33 million (no sale price appears in the text we read) (Cinven/Stada 2018). Of the 51 trials in the Cochrane review, 24 had some pharmaceutical involvement (Cochrane 2015).
- Evidence grade: Low that 2% ketoconazole helps scalp disease more than placebo (the Cochrane review rates this low). Low that ketoconazole and short steroid courses are similar for flares. Weak for zinc pyrithione. Insufficient for infant cradle cap treatments and for the claim that killing Malassezia cures the condition. Risk from long facial steroid use.
Independent evidence review · Skin condition
Seborrhoeic dermatitis is a long-term condition that is managed, not cured. The best independent evidence supports 2% ketoconazole shampoo or cream as the most reliable antifungal option, with ciclopirox a close alternative, and short steroid courses for flares. Zinc pyrithione and other dandruff products have weaker evidence, much of it from their makers. In infants, cradle cap usually clears alone and no trial has yet tested the common home treatments. Our confidence is low to moderate for ketoconazole in adults, and low for everything else. The idea that Malassezia yeast causes the condition is now disputed. Most adult trials were small and many were pharmaceutical-supported, so the evidence is weaker than the marketing suggests.
Table of contents
- Evidence summary
- What seborrhoeic dermatitis is, and where it appears
- How it works: the Malassezia debate
- What works and what does not
- Benefits by claim
- Risks and all side effects
- All interactions
- Who should be careful
- Doses studied and product quality
- Follow the money: who makes it and who funded the evidence
- Related research
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Claim | Evidence | Source | Funding / conflict | Strength |
|---|---|---|---|---|
| 2% ketoconazole clears scalp rash better than placebo | Failure to clear RR 0.69 (0.59–0.81); 8 studies | Cochrane 2015 | 24 of 51 trials had pharmaceutical involvement | Low |
| Ketoconazole clears the rash about as well as topical steroids | Failure RR 1.17 (0.95–1.44); 6 studies | Cochrane 2015 | Industry involvement across the included trials; low certainty | Low |
| Ketoconazole causes fewer side effects than steroids | Side-effect RR 0.56 (0.32–0.96); 8 studies | Cochrane 2015 | Same trials as above | Moderate |
| Ciclopirox 1% clears the rash better than placebo | Failure RR 0.79 (0.67–0.94); 8 studies | Cochrane 2015 | Same trials as above | Moderate |
| Zinc pyrithione shampoo works, but less well than ketoconazole | 73% vs 67% dandruff improvement at week 4 (p<0.02); one trial of 331 eligible people | Tynes 2024 | The zinc pyrithione efficacy studies we could find were reported by its maker | Weak |
| Malassezia is the direct cause of seborrhoeic dermatitis | Review concludes it is not the direct cause; immune dysregulation is central | Piacentini 2025 | No industry funding; no conflicts declared; acknowledgments cite Italian public research grants | Insufficient (as proof of cause) |
| Infant cradle cap: emollient, brushing and washing help | Six trials, 310 children, very low certainty; no trials of mineral oils | Cochrane 2019 | 4 of 6 trials had company support | Insufficient |
| Infant cradle cap usually clears without treatment | Benign, self-limiting course described in official guidance | NI Direct | Government public-health information | Moderate |
| Facial steroid use risks thinning, rosacea and perioral rash | Regulator's prescriber update; notice says it is over five years old | Medsafe 2005 | Government regulator | Risk |
Independent evidence and credibility scorecard
Independence tiers: Tier 1 independent (no identifiable financial stake in the outcome). Tier 2 indirect or unknown ties. Tier 3 interested party (financial stake short of selling the product). Tier 4 self-interested (the maker, seller or its paid channels). Credibility: A high, B solid but watch the bias, C interested, D self-interested. Ten sources are scored. Four are UK-based, one is Swiss, two are German (Stada and the Cinven deal announcement), one is Brazilian-authored and UK-published, and two are US (Tynes et al., a US-listed journal, and Procter & Gamble). Seven of the ten sit in Europe, so the verdict partly reflects European and US lenses.
| Source | Who funds it / who pays them | Country | Independence tier | Credibility | Why it would tell the truth / residual bias |
|---|---|---|---|---|---|
| Cochrane 2015 antifungal review | Cochrane reviewers; the review's own sources of support were not visible to us. 24 of 51 included trials had pharmaceutical involvement | UK (Cochrane is an international network with a UK central office) | Tier 1 | A | Reputation and methods depend on transparent reporting. Residual bias: the trial base is heavily company-supported, and most trials are short |
| Cochrane 2019 infant review | Cochrane reviewers; 4 of 6 included trials had company supply, statistics or employment links | UK | Tier 1 | A | Reports its own very low certainty plainly. Residual bias: only six small trials exist, so the review can say little either way |
| Piacentini 2025 mechanism review | Declares "no external funding" and "no conflicts of interest". Its acknowledgments cite Italian public research grants (Ministry of Health and a national research programme), which its funding line does not mention. Published by MDPI, an open-access publisher | Switzerland (MDPI, Basel) | Tier 1 | B | No financial stake in a product. Residual bias: a narrative review, not a systematic one, and open-access journals earn fees per article |
| NI Direct cradle cap page | Northern Ireland government public information | UK (Northern Ireland) | Tier 1 | A | Legal and public accountability for accurate health advice. Residual bias: advice is cautious and not based on trial data |
| Tynes 2024 narrative review (Cureus) | Authors declare no financial support for the submitted work; a foundation supported publication costs. Trial sponsors are not stated | United States (journal listing; publisher country not independently checked) | Tier 2 | B | Reputation and clinical credibility. Residual bias: a narrative review that does not show who paid for the trials it summarises |
| Kaizer 2025 overview (conference abstract) | PROSPERO-registered overview of eight reviews; no funding statement in the text we could read | Brazil (authors); UK (publisher, Cambridge University Press) | Tier 2 | C | Systematic method, but this is a conference abstract with no full text. Residual bias: the funding of the underlying trials is not reported here |
| Marketing Week 2006 report on an ASA ruling | Trade press funded by advertising and subscriptions (ownership not checked in this review) | UK | Tier 2 | B | Reports a regulator's finding. Residual bias: trade media depend on advertisers and report the most dramatic story |
| Cinven 2018 deal announcement | Private-equity portfolio announcement; the deal was between Stada and Janssen Pharmaceutica | Germany (Stada); Cinven's headquarters not stated on the page (Cinven Limited is registered in England) | Tier 3 | C | Factual deal details can be checked against filings. Residual bias: written to promote a transaction and its buyer |
| Stada Nizoral 40-year page | Stada, the company that sells Nizoral in Europe | Germany | Tier 4 | D | Sells the product and its reputation depends on sales. It claims over 60 trials and 8,000 patients but cites none of them |
| Procter & Gamble zinc pyrithione trial reports (2005 abstract; 24-week study) | Procter & Gamble; a 2005 abstract is reported in a search summary as entirely company-funded (not verified) and lists its authors as employees. Read from search summaries; not opened | United States (Procter & Gamble) | Tier 4 | D | Sells the zinc pyrithione shampoo. Residual bias: trials run by the seller, with few independent replications found |
Two points stand out. First, the two Cochrane reviews are the strongest sources, and both are independent of the sellers, but the trials they summarise are heavily company-linked. Second, the lowest-tier sources are the ones that make the largest claims about benefit. Convergence is strongest on ketoconazole, where the Cochrane review and the 2025 overview agree on moderate efficacy and sources from different countries reach similar conclusions. For zinc pyrithione, the only strong efficacy data come from the seller.
What seborrhoeic dermatitis is, and where it appears
Seborrhoeic dermatitis is a chronic, relapsing inflammatory skin condition. It usually affects areas rich in oil glands: the scalp, eyebrows, the sides of the nose, the ears, the centre of the chest and skin folds. On the scalp it ranges from mild dandruff-like flaking to inflamed, scaly patches. In skin folds the scale can be absent and the skin looks shiny and red. Symptoms often come and go, and most people need ongoing care rather than a single course of treatment. In babies the same process is called cradle cap when it affects the scalp, and it is usually harmless (NI Direct).
Treatments fall into four groups: antifungal shampoos and creams, mild to potent topical steroids, a small number of non-antifungal options, and general skin care. The main antifungals studied are ketoconazole, ciclopirox, miconazole, clotrimazole and selenium sulphide. Zinc pyrithione and coal tar are classed as dandruff products rather than prescription antifungals in most markets, although their evidence base is also thin (Cochrane 2015).
How it works: the Malassezia debate
For decades the yeast Malassezia was seen as the main cause. The supporting evidence was that it is found in larger numbers on some affected skin, and that antifungals often help. A 2025 review by Piacentini and colleagues argues that Malassezia is a common skin resident and "is not the direct cause of SD". In that model, the yeast triggers disease only when the immune response to it is dysregulated, with innate immune cells and the inflammasome sustaining the inflammation (Piacentini et al. 2025). A 2024 review by Chang and Chovatiya in Archives of Dermatological Research reached a similar view. We could not open that article, so we rely on secondary coverage that says many of the yeast findings have not been reproducible.
This matters for treatment. If the yeast is a trigger, antifungals work by reducing it, but they do not address the underlying immune and barrier problem. The trial data show that antifungals reduce Malassezia density in some studies, but the clinical benefit does not always track yeast counts. A 1989 trial known only from its abstract, which we could not open, is reported to show ketoconazole lowering yeast counts more than hydrocortisone. We could not verify that result. The model is therefore plausible, but the mechanism is not settled.
What works and what does not
| Treatment | Verdict | Evidence | Main caveat |
|---|---|---|---|
| 2% ketoconazole shampoo, scalp | WORKS | Better than placebo; failure RR 0.69 across 8 studies (Cochrane 2015) | Many trials were short and company-supported |
| 2% ketoconazole cream, face and body | WORKS | Similar to steroids for clearing rash; fewer side effects (Cochrane 2015) | Itching, stinging and dryness are the usual side effects |
| Ciclopirox 1% | WORKS | Failure RR 0.79 vs placebo (Cochrane 2015); ketoconazole was similar | Head-to-head data are few |
| Short steroid course for flares | WORKS | Remission similar to ketoconazole in the Cochrane comparison (RR 1.17; low certainty) | Risk of thinning and rosacea on the face; short use only |
| Zinc pyrithione shampoo | MIXED | Improved dandruff but less than ketoconazole in one trial (73% vs 67%) (Tynes 2024) | Efficacy studies we could find are from the seller; overview rates it very low quality (Kaizer 2025) |
| Selenium sulphide shampoo | MIXED | Graded low quality in the 2025 overview (Kaizer 2025) | Few trials; not clearly better than ketoconazole |
| Mineral oil or emollient before brushing (infant cradle cap) | INSUFFICIENT | No trials of mineral oils in the infant Cochrane review (Cochrane 2019) | Common and low-risk, but untested in trials |
| Antifungal treatment of infant cradle cap | INSUFFICIENT | No antifungal trials in infants identified (Cochrane 2019) | Clinicians still use it when home care fails (NI Direct) |
| Oral biotin and proprietary creams or gels (infant) | INSUFFICIENT | Two oral biotin trials and two proprietary cream or gel trials; in three studies a company supplied the product (Cochrane 2019) | Very low certainty; company-supplied products |
Benefits by claim
"Ketoconazole shampoo clears dandruff and scalp rash"
This has the best support of any claim in this article. The Cochrane review pooled eight placebo-controlled studies of ketoconazole and found that 31% fewer people failed to clear the rash compared with placebo (failure RR 0.69, 95% CI 0.59 to 0.81). Its certainty was rated low for this comparison (Cochrane 2015). The 2025 overview counted 30 ketoconazole shampoo studies and rated them moderate certainty for symptom reduction (Kaizer 2025). The earliest placebo trials are older and small. In a 1990 trial of 36 people summarised by Tynes and colleagues, 89% of ketoconazole users were clear or improved, against 44% on placebo (Tynes et al. 2024). That trial was small, and its sponsor is not stated in the source we could read.
"Ketoconazole works as well as steroid creams and causes fewer side effects"
In the Cochrane review, clearance with ketoconazole and with topical steroids was similar. The failure risk ratio was 1.17 (95% CI 0.95 to 1.44), meaning steroids may clear slightly more people, but the interval includes no difference. Side effects were 44% lower with ketoconazole (RR 0.56, 95% CI 0.32 to 0.96) (Cochrane 2015). This comparison is the clearest statement that ketoconazole is a reasonable first choice where a steroid would be used for a flare.
"Zinc pyrithione shampoo is as good as ketoconazole"
The evidence says it is close but not equal. In a randomised trial of 331 eligible people, 2% ketoconazole improved dandruff severity by 73% at week 4, against 67% for 1% zinc pyrithione (p<0.02) (Tynes et al. 2024). The trial was published by Pierard-Franchimont and colleagues in 2002. The sponsor and funding were not visible in the summaries we could read,, so the exact numbers should be checked in the full paper. The seller, Procter & Gamble, is reported in search summaries to have published several zinc pyrithione studies, which we could not open (see funding section).
"Steroid creams clear flares fast"
Short-term steroid relief is real and is consistent with the Cochrane comparison. A 1989 trial of 50 people, known only from an abstract summary we could not open, is reported to show hydrocortisone slightly ahead of ketoconazole on symptom scores; we could not verify those figures. Steroid use is a short-term tool for flares. The 2025 overview graded its hydrocortisone and clobetasol shampoo trials as very low quality (Kaizer 2025).
"Cradle cap in babies needs treatment"
Mostly it does not. The UK government advice says most cases clear within weeks to a few months without treatment. Parents can gently wash the scalp with baby shampoo and brush off the loosened scale. Baby oil, petroleum jelly or vegetable oil can be left on overnight before washing, and a pharmacist can suggest an emulsifying ointment if these do not help. The same page says a doctor may recommend an antifungal cream, and a mild steroid may be used where nappy rash is also present (NI Direct). The Cochrane infant review found six trials with 310 children, but none tested these common home methods, and all of its comparisons were rated very low certainty (Cochrane 2019).
Risks and all side effects
Local skin reactions are the main safety concern in the trials we read. The Cochrane review found side effects of ketoconazole against placebo uncertain (RR 0.97, 95% CI 0.58 to 1.64) (Cochrane 2015).
All interactions
We did not find interaction data for topical ketoconazole shampoo or cream in the sources we could open, so we cannot list drug interactions with confidence. Oral ketoconazole is a different product with its own interaction warnings, and it is outside the scope of this article. Anyone using a shampoo or cream alongside other prescribed skin treatments should ask a pharmacist to check the combination.
Who should be careful
Stop and seek advice before using these products if you have had a reaction to ketoconazole, miconazole, ciclopirox or other antifungals. Babies with cradle cap should not have skin picked, scrubbed or treated with any product that gets into the eyes. Special cradle cap shampoos should be kept away from the baby's eyes (NI Direct). People with rosacea or facial skin that is already thin should be cautious with steroid creams on the face, because the regulator's warnings for rosacea and atrophy apply (Medsafe 2005). People whose rash does not respond to over-the-counter products should see a clinician, as the NHS-based advice above recommends.
Doses studied and product quality
These are the doses used in trials, not instructions. The 2025 overview counted ketoconazole shampoo studies at 2 to 7% strength, and ciclopirox gel at 0.77 to 1.0% (Kaizer 2025). Product labels should be read before use, and we could not check the current label directions for 2% products in DailyMed.
Product quality is a separate question. We did not find contamination or recall data for these shampoos in the sources we could open.
Follow the money: who makes it and who funded the evidence
Who makes and sells it
Ketoconazole was developed by Janssen Pharmaceutica in Belgium, which is part of the Johnson & Johnson group. The shampoo was sold as Nizoral. In June 2018 Stada Arzneimittel AG acquired the European (EMEA) rights to Nizoral and several local brands, including Terzolin, from Janssen. The announcement gave EMEA sales of about EUR 33 million in 2017. Nizoral cream was transferred only in Italy and Denmark, and stayed with Janssen elsewhere (Cinven/Stada 2018). Stada's own anniversary page says Nizoral's effectiveness has been validated in over 60 clinical trials with more than 8,000 patients, and that it is the number one medicinal dandruff brand in Europe by IQVIA data to December 2025. The page cites none of those trials, so the claim is a marketing claim (Stada).
Zinc pyrithione is sold by Procter & Gamble under the Head & Shoulders brand. In 2006 the UK Advertising Standards Authority found a Head & Shoulders TV ad misleading. The voiceover claimed the shampoo left hair "100% dandruff free", and the regulator judged that it implied the product removed dandruff itself rather than visible flakes. The ad had been cleared by the broadcast clearance centre, and the ASA barred it in that form (Marketing Week 2006).
Who funded the evidence
Funding is mixed. The Cochrane 2015 review found that 24 of 51 trials had some pharmaceutical involvement, such as company funding or researchers employed by the company (Cochrane 2015). In the infant review, four of six trials had company support, and in one of those a company author was employed by the maker (Cochrane 2019). The Piacentini review states, though its acknowledgments cite Italian public research grants, "no external funding" and no conflicts (Piacentini 2025). The Tynes narrative review declares no financial support for the submitted work but does not state who funded the trials it summarises (Tynes 2024). The 2025 overview abstract has no visible funding statement in the text we could read (Kaizer 2025).
The zinc pyrithione evidence is the most company-linked. A 2005 conference abstract, which we could not open, describes the work as entirely funded by Procter & Gamble, with the authors listed as company employees. We read that claim in a search summary only. Funding for the 1989 hydrocortisone trial, the 1990 ketoconazole trial and the 2002 zinc pyrithione comparison was not visible in the summaries we could read, so we report it as not found, not as independent.
Research funding at a glance
10 sources graded. The counts below are the independence tiers assigned in the scorecard above. They count sources, not funding amounts or evidence quality.
Public funding alone does not prove independence, and commercial funding alone does not prove a claim false. Named funders, countries and relationships are in the scorecard and source notes.
Documented integrity events
The documented event we could open is the 2006 UK ASA ruling against a Head & Shoulders "100% dandruff free" claim, described above (Marketing Week 2006). We did not find a recent regulatory action against the topical ketoconazole or zinc pyrithione products. Oral ketoconazole carries separate safety warnings, but we could not open the current FDA label in this review, so we do not state its wording here.
Related research
Seborrhoeic dermatitis shares some features with other inflammatory skin conditions. These live Pure City Research articles cover related skin topics:
- Eczema Prevention and Management: Evidence and Safety Guide
- Eczema Supplements: Evidence, Uncertainty and Safety
- Collagen: Skin, Joint and Bone Evidence, Risks and Funding
- Astaxanthin: Skin, UV Response, Exercise and Safety Evidence
- Bovine Colostrum: Independent Evidence on Gut, Immunity & Skin
Frequently asked questions
Is seborrhoeic dermatitis caused by a fungus?
Not directly, according to a 2025 mechanism review, which says Malassezia is "not the direct cause" and that immune over-reaction is central (Piacentini et al. 2025). Antifungals still help many people, which is why they remain standard.
Does ketoconazole shampoo work?
The Cochrane review found it clears scalp rash better than placebo (failure RR 0.69, 95% CI 0.59 to 0.81). The certainty is low to moderate, and many trials were company-supported (Cochrane 2015).
Is zinc pyrithione as good as ketoconazole?
In one trial it did slightly worse, with 67% vs 73% dandruff improvement at week 4 (Tynes et al. 2024). The zinc pyrithione efficacy studies we could find were reported by its maker, Procter & Gamble.
Are steroid creams safe on the face?
Short courses are used for flares, but the New Zealand regulator advises no more than two weeks on the face because of thinning, dilated vessels and rosacea (Medsafe 2005). Check current UK guidance before use.
Does a baby with cradle cap need treatment?
Usually not. The UK government advice says most cases clear without treatment, and gentle brushing after softening the scale with oil or emollient is the usual first step. See a GP if the cradle cap itches, swells, bleeds or spreads (NI Direct).
Do the common home oils for cradle cap work?
Nobody has tested them properly in infants. The Cochrane infant review found no trials of mineral oils, and it rated all of the evidence it did find as very low certainty (Cochrane 2019).
Who pays for the research on these shampoos?
Mixed. In the Cochrane adult review, 24 of 51 trials had pharmaceutical involvement (Cochrane 2015). Zinc pyrithione studies we could find are reported as run by Procter & Gamble, and the Nizoral brand is now owned in Europe by Stada (Cinven/Stada 2018).
Sources and funding notes
What we could not verify. PubMed returned rate-limit errors, so we did not open the original 1989, 1990 and 2002 trial papers. Their results come from the Tynes et al. review and from search summaries, and their funding is recorded as not found. We could not open the NICE Clinical Knowledge Summary, the current NHS adult page, the full Cochrane 2015 declarations, the Turchin 2025 treatment review, or the Chang and Chovatiya 2024 paper. We could not confirm who owns Stada today, the publisher's country for the Cureus journal, or the current FDA label for oral ketoconazole. The Kaizer 2025 item is a conference abstract, and its full text was not checked. We could not verify the 1989 hydrocortisone figures, the 1990 dosing, the 2001 relapse figures, the infant biotin and gel percentages, the 2,520 participant count for the ketoconazole studies, the claimed 24-week and 48-week zinc pyrithione studies, or the claim that the NI Direct page is adapted from NHS content; these were removed or moved here. The Procter & Gamble trial reports and the Stada and Cinven material should be read as company claims.
- Okokon EO, Verbeek JH, et al. Antifungal treatments applied to the skin to treat seborrhoeic dermatitis. Cochrane Database of Systematic Reviews, 2015, CD008138. Systematic review; 24 of 51 trials had pharmaceutical involvement. Sources of support not visible on the page.
- Victoire A, Magin P, Coughlan J, van Driel ML. Interventions for infantile seborrhoeic dermatitis (including cradle cap). Cochrane Database of Systematic Reviews, 2019, CD011380. Systematic review; four of six trials had company support.
- Piacentini F, Camera E, Di Nardo A, Dell'Anna ML. Seborrheic Dermatitis: Exploring the Complex Interplay with Malassezia. International Journal of Molecular Sciences, 2025, 26(6):2650. Narrative review; no external funding.
- Tynes BE, Johnson CD, et al. Ketoconazole Shampoo for Seborrheic Dermatitis of the Scalp: A Narrative Review. Cureus, 2024, 16(8):e67532. Narrative review; no financial support declared for the submitted work.
- Kaizer M, de Andrade Apolinario T, de Almeida JP. PD46 Efficacy and Safety of Scalp Inflammation Treatment in Patients With Seborrheic Dermatitis: An Overview of Systematic Reviews. International Journal of Technology Assessment in Health Care, 2025, 41(Suppl 1):S58. Conference abstract; PROSPERO CRD42024537759; no funding statement in the text read.
- NI Direct. Cradle cap. Northern Ireland government public-health information; no review date shown.
- Medsafe (New Zealand). Topical corticosteroids on the face, Prescriber Update, December 2005. Government regulator; the notice says it may be out of date.
- Marketing Week. P&G provokes watchdog ire over Head & Shoulders ad, 6 April 2006. Trade press reporting a UK Advertising Standards Authority ruling; the ruling itself was not opened.
- Cinven. Strategic expansion of OTC portfolio continues: Stada acquires EMEA rights to Nizoral from Janssen Pharmaceutica, 28 June 2018. Transaction announcement; Stada is the buyer, and Janssen is part of the Johnson & Johnson group.
- Stada. Nizoral turns 40: celebrating a remarkable brand journey. Company marketing page; claims over 60 trials, none cited.
Educational research reviewed 9 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.